Ibrutinib and Idelalisib For CLL
The mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL).
Thomas Kipps, MD, PhD, Division of Hematology-Oncology Deputy Director for Research at the UC San D...
Author: onclivetv
Added: 03/06/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia